Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Mithra Pharmaceuticals S.A.    MITRA   BE0974283153

MITHRA PHARMACEUTICALS S.A.

(MITRA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
19.7(c) 18.88(c) 18.86(c) 18.5(c) 18.84 Last
91 041 65 145 26 328 32 999 25 442 Volume
+4.01% -4.16% -0.11% -1.91% +1.84% Change
More quotes
Financials
Sales 2020 66,1 M 74,9 M 74,9 M
Net income 2020 -12,7 M -14,3 M -14,3 M
Net Debt 2020 65,5 M 74,1 M 74,1 M
P/E ratio 2020 -63,2x
Yield 2020 -
Sales 2021 96,1 M 109 M 109 M
Net income 2021 34,3 M 38,9 M 38,9 M
Net Debt 2021 54,0 M 61,1 M 61,1 M
P/E ratio 2021 7,46x
Yield 2021 -
Capitalization 787 M 891 M 892 M
EV / Sales 2020 12,9x
EV / Sales 2021 8,75x
Nbr of Employees 172
Free-Float 53,0%
More Financials
Company
Mithra Pharmaceuticals S.A. specializes in the development of women's health care products that are dedicated to the fields of contraception, fertility, and menopause. The three lead development candidates Estelle® (a fifth generation oral contraceptive), PeriNesta? (first full oral treatment against perimenopause) and Donesta® (a next generation hormone therapy) are built on Mithra's unique natural estrogen... 
Sector
Pharmaceuticals
Calendar
09/24Earnings Release
More about the company
Surperformance© ratings of Mithra Pharmaceuticals S.A
Trading Rating : - Investor Rating :
More Ratings
Latest news on MITHRA PHARMACEUTICALS S.A
07/10MITHRA PHARMACEUTICALS S A : - Publication of a Transparency Notification Receiv..
AQ
07/07MITHRA PHARMACEUTICALS S A : Signs LSA for Commercialization of Myring in France..
AQ
06/25Mithra Announces FDA Filing Acceptance of New Drug Application for Estelle in..
AQ
06/25MAYNE PHARMA : Announces FDA Filing Acceptance of New Drug Application for E4/DR..
AQ
06/24MITHRA PHARMACEUTICALS S A : Announces FDA Filing Acceptance of New Drug Applica..
PU
06/23MITHRA PHARMACEUTICALS S.A. : Threshold crossings
CO
06/19MITHRA PHARMACEUTICALS S A : Notice of Extraordinary Shareholders' Meeting on 22..
PU
06/19GLOBAL MARKETS LIVE: L’Oréal, Hertz, Facebook…
06/18MITHRA PHARMACEUTICALS S A : Successfully Raises EUR 65 Million By Means of a Pr..
PU
06/18MITHRA PHARMACEUTICALS S A : Launches Capital Increase By Means of a Private Pla..
PU
06/12MITHRA PHARMACEUTICALS S A : Signs LSA for Commercialization of Tibelia in Liech..
AQ
06/08MITHRA PHARMACEUTICALS S A : Issues First Put Option Notice Under Capital Agreem..
AQ
06/05MITHRA PHARMACEUTICALS S A : Issues First Put Option Notice Under Capital Agreem..
PU
05/29MAYNE PHARMA : signs license agreement for contraceptive in Australia
AQ
05/28MITHRA PHARMACEUTICALS S A : Signs License and Supply Agreement with Mayne Pharm..
PU
More news
News in other languages on MITHRA PHARMACEUTICALS S.A
07/10MITHRA PHARMACEUTICALS S A : - Publication of a Transparency Notification Receiv..
07/07MITHRA PHARMACEUTICALS S A : Signs LSA for Commercialization of Myring in France..
07/06MITHRA PHARMACEUTICALS S A : signe un accord de licence et d'approvisionnement p..
06/25Mithra Announces FDA Filing Acceptance of New Drug Application for Estelle in..
06/25MAYNE PHARMA : Announces FDA Filing Acceptance of New Drug Application for E4/DR..
More news
Chart MITHRA PHARMACEUTICALS S.A.
Duration : Period :
Mithra Pharmaceuticals S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MITHRA PHARMACEUTICALS S.A
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 27,98 €
Last Close Price 18,50 €
Spread / Highest target 89,2%
Spread / Average Target 51,2%
Spread / Lowest Target -45,9%
EPS Revisions
Managers
NameTitle
François Fornieri Chief Executive Officer & Executive Director
M. A. A. A. Liliane Coucke Chairman
Christophe Maréchal Chief Financial Officer
Patrick Kellens Chief Information Officer
Graham K. Dixon CSO, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
MITHRA PHARMACEUTICALS S.A.-29.55%891
CSL LIMITED2.40%89 140
BIOGEN INC.-6.02%45 510
SAMSUNG BIOLOGICS CO.,LTD.68.82%40 291
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.125.11%25 551
WUXI BIOLOGICS (CAYMAN) INC.47.39%25 413